Ana BelÃ©n Herrero

List of Publications by Year
in descending order

24 papers	898 citations	471509 17 h-index	610901 24 g-index
24 all docs	24 docs citations	24 times ranked	1743 citing authors

#	Article	IF	Citations
1	Chloroquine-Induced DNA Damage Synergizes with Nonhomologous End Joining Inhibition to Cause Ovarian Cancer Cell Cytotoxicity. International Journal of Molecular Sciences, 2022, 23, 7518.	4.1	4
2	Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy. International Journal of Molecular Sciences, 2021, 22, 1907.	4.1	7
3	Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair. Neoplasia, 2021, 23, 515-528.	5.3	16
4	FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma. Journal of Cellular and Molecular Medicine, 2020, 24, 4171-4182.	3.6	24
5	CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia, 2020, 34, 1599-1612.	7.2	21
6	Clinical and Biological Impact of TP53 Alterations in Del(11q) Chronic Lymphocytic Leukemia. Blood, 2020, 136, 6-7.	1.4	1
7	Factors Regulating microRNA Expression and Function in Multiple Myeloma. Non-coding RNA, 2019, 5, 9.	2.6	29
8	Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. Haematologica, 2017, 102, 168-175.	3.5	9
9	DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. Journal of Hematology and Oncology, 2017, 10, 92.	17.0	23
10	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. Journal of Hematology and Oncology, 2017, 10, 127.	17.0	25
11	Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival. Frontiers in Oncology, 2017, 7, 98.	2.8	36
12	Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. International Journal of Molecular Sciences, 2016, 17, 2003.	4.1	59
13	Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma. American Journal of Pathology, 2016, 186, 2171-2182.	3.8	35
14	Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair. Oncotarget, 2016, 7, 30440-30452.	1.8	19
15	Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability. PLoS ONE, 2015, 10, e0121581.	2.5	44
16	Npl3, a new link between RNA-binding proteins and the maintenance of genome integrity. Cell Cycle, 2014, 13, 1524-1529.	2.6	8
17	The Npl3 hnRNP prevents R-loop-mediated transcriptionâ€"replication conflicts and genome instability. Genes and Development, 2013, 27, 2445-2458.	5.9	72
18	Lsm1 promotes genomic stability by controlling histone mRNA decay. EMBO Journal, 2011, 30, 2008-2018.	7.8	49

#	Article	IF	Citations
19	Levels of <i>SCS7/FA2H</i>-Mediated Fatty Acid 2-Hydroxylation Determine the Sensitivity of Cells to Antitumor PM02734. Cancer Research, 2008, 68, 9779-9787.	0.9	57
20	Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin. Cancer Research, 2006, 66, 8155-8162.	0.9	168
21	KRE5 Gene Null Mutant Strains of Candida albicans Are Avirulent and Have Altered Cell Wall Composition and Hypha Formation Properties. Eukaryotic Cell, 2004, 3, 1423-1432.	3.4	73
22	The Golgi GDPase of the Fungal Pathogen Candida albicans Affects Morphogenesis, Glycosylation, and Cell Wall Properties. Eukaryotic Cell, 2002, 1, 420-431.	3.4	50
23	Candida albicans and Yarrowia lipolytica as alternative models for analysing budding patterns and germ tube formation in dimorphic fungi. Microbiology (United Kingdom), 1999, 145, 2727-2737.	1.8	32
24	Control of Filament Formation in <i>Candida albicans</i> by Polyamine Levels. Infection and Immunity, 1999, 67, 4870-4878.	2.2	37